NCT04616677View on ClinicalTrials.gov

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

October 18, 2022

Study Completion Date

October 18, 2022

Conditions
Renal Impairment
Interventions
DRUG

JNJ-42847922

JNJ-42847922 tablet will be administered orally.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

37923

AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04616677 - A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants | Biotech Hunter | Biotech Hunter